Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.61 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.60 |
| ▸ | PLD2 | O14939 | 1/20 | 0.60 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575582 | 0.99 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL13175532 | 0.98 | SMN1; SMN2 (0.65) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL12427422 | 0.93 | SLC29A1 (0.66) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL12426657 | 0.92 | SLC29A1 (0.65) | SMN1; SMN2POLBKMT2AHTR4F10 | |
| SCHEMBL12426361 | 0.92 | KMT2A (0.65) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL12427419 | 0.91 | HTR4 (0.65) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL3543383 | 0.90 | CYP2C9 (0.71) | POLBKMT2AHTR4PLD2PLD1 | |
| SCHEMBL14924433 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2POLBKMT2ASLC5A7NPSR1 | |
| SCHEMBL14452318 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBKMT2AHTR4SLC5A7 | |
| SCHEMBL12427360 | 0.85 | CYP2D6 (0.64) | SMN1; SMN2KMT2AHTR4PLD2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585470-B1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO LTD (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-2975042-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009130016-A1 | DIHYDROPTERIDINONES AS PLK INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112152-A1 | Dihydropteridinones as Plk Inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | SMN1; SMN2 1059/4885POLB 3906/4885KMT2A 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.